Accès ouvert
2023
article
OpenAlex
Liangliang Wu, Yiming Gao, Shengzhi Xie, Ye Wan et autres
PURPOSE: This study aimed to screen biomarkers to predict the efficacy of programmed cell death 1 (PD-1) blockade immunotherapy combined with chemotherapy as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC). METHODS: In the first stage of the study, the baseline concentrations …
cn, jp
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Chunyu Wang, Shuai Mu, Xuhui Yang, Lingling Li et autres
Objectives: Brain metastases (BMs) are common in extensive-stage small-cell lung cancer (SCLC) and are underrepresented in pivotal clinical trials that demonstrate the efficacy of immune checkpoint inhibitors (ICIs). We conducted a retrospective analysis to assess the role of ICIs in BM lesions …
cn
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Xuan Zheng, Shuai Mu, Lijie Wang, Haitao Tao et autres
BACKGROUND: Patients with pulmonary large cell carcinoma (LCC) have a high incidence of synchronous brain metastases (SBM) and a poor prognosis. Our study was to evaluate the predictive and prognostic value of the clinical characteristics of pulmonary LCC patients with SBM at …
cn
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Xuan Zheng, Shuai Mu, Lijie Wang, Haitao Tao et autres
Abstract Background: Patients with pulmonary large cell carcinoma (LCC) have a high incidence of synchronous brain metastases (SBM) and a poor prognosis. Our study was to evaluate the predictive and prognostic value of the clinical characteristics of pulmonary LCC patients with SBM …
cn
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Lingling Li, Tingting Liu, Qingyan Liu, Shuai Mu et autres
Background: Rechallenge of immunotherapy beyond progression (RIBP) has been demonstrably effective in a variety of cancers. Our study aims to investigate the efficacy of RIBP in small-cell lung cancer (SCLC) patients under real-world conditions. Methods: SCLC patients who experienced progressive disease after …
cn
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Jinzhao Zhai, Jiangyue Lu, Zhibo Zhang, Yuan Wang et autres
Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non-squamous non-small cell lung cancer (NS-NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI plus chemotherapy (ICI-chemotherapy) and bevacizumab plus chemotherapy …
cn
(code pays fourni par la source)
2021
conference-abstract
OpenAlex
Zhibo Zhang, Jinzhao Zhai, Xiang Yan, Fan Zhang et autres
e21152 Background: Chemotherapy in combination with PD-1/PD-L1 inhibitor or bevacizumab have demonstrated superior efficacy to chemotherapy in the first-line treatment for non-squamous non-small-cell lung cancer (NS-NSCLC). However, there has been no randomized study comparing PD-1/PD-L1 inhibitors plus chemotherapy (immune-chemo) with bevacizumab plus …
cn
(code pays fourni par la source)